BIIB vs. MOH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BIIB and MOH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BIIB | MOH |
|---|---|---|
| Company Name | Biogen Inc. | Molina Healthcare, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 22.13 billion USD | 11.00 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | September 17, 1991 | July 2, 2003 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BIIB and MOH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BIIB | MOH |
|---|---|---|
| 5-Day Price Return | -2.76% | 4.46% |
| 13-Week Price Return | 13.49% | -14.46% |
| 26-Week Price Return | 15.50% | -42.55% |
| 52-Week Price Return | -17.66% | -37.61% |
| Month-to-Date Return | 7.77% | 6.04% |
| Year-to-Date Return | -1.28% | -30.28% |
| 10-Day Avg. Volume | 1.99M | 0.96M |
| 3-Month Avg. Volume | 1.51M | 1.36M |
| 3-Month Volatility | 37.07% | 55.12% |
| Beta | 0.12 | 0.52 |
Profitability
Return on Equity (TTM)
BIIB
9.04%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
BIIB’s Return on Equity of 9.04% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
MOH
24.86%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
In the upper quartile for the Health Care Providers & Services industry, MOH’s Return on Equity of 24.86% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
BIIB
15.31%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
BIIB’s Net Profit Margin of 15.31% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
MOH
2.60%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
MOH’s Net Profit Margin of 2.60% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BIIB
20.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
BIIB’s Operating Profit Margin of 20.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
MOH
3.81%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
MOH’s Operating Profit Margin of 3.81% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BIIB | MOH |
|---|---|---|
| Return on Equity (TTM) | 9.04% | 24.86% |
| Return on Assets (TTM) | 5.43% | 7.06% |
| Net Profit Margin (TTM) | 15.31% | 2.60% |
| Operating Profit Margin (TTM) | 20.80% | 3.81% |
| Gross Profit Margin (TTM) | 75.43% | 14.88% |
Financial Strength
Current Ratio (MRQ)
BIIB
2.50
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
BIIB’s Current Ratio of 2.50 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
MOH
1.66
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
MOH’s Current Ratio of 1.66 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
BIIB
0.36
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.36 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MOH
0.77
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
MOH’s Debt-to-Equity Ratio of 0.77 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
MOH
14.47
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
MOH’s Interest Coverage Ratio of 14.47 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | BIIB | MOH |
|---|---|---|
| Current Ratio (MRQ) | 2.50 | 1.66 |
| Quick Ratio (MRQ) | 1.79 | 1.61 |
| Debt-to-Equity Ratio (MRQ) | 0.36 | 0.77 |
| Interest Coverage Ratio (TTM) | 4.35 | 14.47 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
MOH
0.00%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
MOH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
MOH
0.00%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
MOH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BIIB | MOH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BIIB
14.47
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 14.47 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
MOH
9.79
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
In the lower quartile for the Health Care Providers & Services industry, MOH’s P/E Ratio of 9.79 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BIIB
2.22
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.22 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
MOH
0.25
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
In the lower quartile for the Health Care Providers & Services industry, MOH’s P/S Ratio of 0.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BIIB
1.04
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
BIIB’s P/B Ratio of 1.04 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
MOH
3.51
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
MOH’s P/B Ratio of 3.51 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BIIB | MOH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 14.47 | 9.79 |
| Price-to-Sales Ratio (TTM) | 2.22 | 0.25 |
| Price-to-Book Ratio (MRQ) | 1.04 | 3.51 |
| Price-to-Free Cash Flow Ratio (TTM) | 11.99 | 10.99 |